Develop and manufacture biosimilar medicines for global markets. Focus on therapeutic areas including autoimmune, eye, bone disorders, and cancer. Now — the numbers.
This is an established company with proven profits.
Average growth of 100% a year over the last 4 years. Red columns mark years that ended in a loss.
The gap is $1.3B. In times of high interest rates, a gap like that can squeeze a company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
An investor who bought at the very peak is down 69% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 100% a year on average.
The company’s market value is 64 times its annual profit. Even a small disappointment could hit the price hard.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 37/100.
Today’s price already includes part of tomorrow’s optimism. Report-card grade: 46/100.
On our five-subject report card, ALVO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ALVO does earn real profits — but on our report card it still sits behind its class. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (46/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.